- Senate and House health committee leaders reached an agreement on a five-year reauthorization of the Food and Drug Administration’s (FDA) user fee. The renewal will be part of the short-term continuing resolution, which Congress must pass by October 1 to avoid a government shutdown. The House passed an FDA user fee package in June with added provisions such as diversifying clinical trial participation. Senate Richard Burr later introduced a “clean” user fee package in the Senate that left out what he referred to as “harmful additions.” FDA Commissioner Robert Califf warned this year that if reauthorization isn’t passed, then the agency will have to carry out furloughs. (Articles here and here)
September 23, 2022
Life Sciences